Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Valneva (31/01/2019)

03.02.2019

Valneva: Austrian/French biotech company Valneva SE announced positive initial booster data and final Phase 1 data for its leading, unique Lyme disease vaccine candidate VLA15. To investigate whether a VLA15 booster will elicit an anamnestic response1, Valneva amended its Phase 1 study protocol during 2018, adding a booster dose in a sub-cohort of the Phase 1 study population. At the same time the full Phase 1 study population has been followed-up across all doses for up to one year, providing the final Phase 1 data.  Wolfgang Bender, Chief Medical Officer of Valneva, commented, “These encouraging results support our current development plans and hypothesis for our leading vaccine candidate, VLA15. As a result of these findings, we have included a VLA15 booster in the Phase 2 program that is now underway. Addressing the significant, and growing, unmet medical need caused by Lyme disease is our top priority, VLA15 remains the only Lyme vaccine candidate in clinical development worldwide.”
Valneva: weekly performance: -3.21%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (31/01/2019)


Partners









latest 21st Austria

21st Austria weekly - Valneva (31/01/2019)


03.02.2019


Valneva: Austrian/French biotech company Valneva SE announced positive initial booster data and final Phase 1 data for its leading, unique Lyme disease vaccine candidate VLA15. To investigate whether a VLA15 booster will elicit an anamnestic response1, Valneva amended its Phase 1 study protocol during 2018, adding a booster dose in a sub-cohort of the Phase 1 study population. At the same time the full Phase 1 study population has been followed-up across all doses for up to one year, providing the final Phase 1 data.  Wolfgang Bender, Chief Medical Officer of Valneva, commented, “These encouraging results support our current development plans and hypothesis for our leading vaccine candidate, VLA15. As a result of these findings, we have included a VLA15 booster in the Phase 2 program that is now underway. Addressing the significant, and growing, unmet medical need caused by Lyme disease is our top priority, VLA15 remains the only Lyme vaccine candidate in clinical development worldwide.”
Valneva: weekly performance: -3.21%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (31/01/2019)


Live-Kursliste, BSNgine
 
 
 
 


Bildnachweis

Aktien auf dem Radar: Marinomed Biotech , UBM , Kapsch TrafficCom , Agrana , FACC , Telekom Austria , ATX , Uniqa , ATX Prime , RBI , OMV , Polytec , AMS , Wienerberger , Betbull Holding , startup300 , Fabasoft , DO&CO , bet-at-home.com , Warimpex .


Random Partner

Deutsche Bank X-markets
db-X markets deckt das gesamte Spektrum moderner Anlagemöglichkeiten ab. Mit Zertifikaten, Optionsscheinen und Fonds bietet db-X markets ein breites Angebot an Finanzprodukten basierend auf dem direkten Zugang zum globalen Investment Banking der Deutschen Bank.

>> Besuchen Sie 49 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten